Heart surgeon Copeland joins faculty at UC San Diego

Justine Varieur Cadet | | Health Imaging | Artificial Intelligence
Heart Surgeon Jack Copeland, MD, will join the faculty of the new $227 million Sulpizio Family Cardiovascular Center at the University of California, San Diego in La Jolla.

In 1979, Copeland performed Arizona’s first heart transplant, and in 1985, he became the first surgeon to successfully use the Jarvik 7 artificial heart as a temporary bridge to transplant. The first five implants of this artificial heart had been for permanent use only.

Copeland is a founder and past president of the International Society for Heart and Lung Transplantation. He also performed the first U.S. implant of a pediatric ventricular assist device designed for newborns and small children. Copeland also served as the principal investigator of the 10-year pivotal clinical study of the Total Artificial Heart for SynCardia Systems.

Justine Varieur Cadet

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
How AI and CCTA help heart teams plan ahead before PCI
5 steps for evaluating radiology AI applications
Adaptable AI system detects subtle changes in imaging, has potential across multiple clinical settings
New algorithm models radiologists' eye movements to interpret chest X-rays

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.